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Chronic inflammation is implicated in the progression of DKD to ESRD, but the underlying mechanisms are largely unknown. Little consideration has been given to whether this process varies according to the type of diabetes or the stage of DKD. Previous human studies examining the role of inflammation had major limitations. They were mainly cross-sectional, focused on limited numbers of candidate inflammatory proteins and did not follow participants to ESRD 2, 3 . Our findings from follow-up studies draw attention to the importance of systemic inflammatory factors as predictors of DKD progression. We showed a strong association between circulating tumor necrosis factor receptors 1 and 2 (TNF-R1 and TNF-R2) and rate of renal decline or time of onset of ESRD [4] [5] [6] . Our findings were replicated in multiple studies [7] [8] [9] [10] [11] . Recently we showed that plasma TNF-R1 itself is a good prognostic marker of progression to ESRD in both types of diabetes 12 .
Our previous findings do not, however, establish which circulating inflammatory proteins are involved in the etiology of DKD, because prognostic modeling overlooks inflammatory proteins that are weaker or collinear with the strongest drivers of the disease process. Therefore, the prognostic approach limits our ability to identify other critical inflammatory proteins involved in DKD progression, which might be important for identifying new therapeutic targets. Accordingly, the aim of the present study was to identify plasma inflammatory proteins associated with the development of ESRD in the Joslin Kidney Study cohorts with type 1 diabetes (T1D) and type 2 diabetes (T2D), so an etiological model for the putative inflammatory process could be developed. We accomplished this aim by measuring concentrations of a comprehensive roster of 194 inflammatory proteins using a custom-designed SOMAscan platform 13, 14 . This array comprised most of the circulating inflammatory proteins known in the literature and most proteins previously studied in the context of DKD. To replicate the Joslin findings, we conducted an identical proteomics study in an independent cohort of Pima Indians with T2D. In all three cohorts followed for 8-11 years, the outcome measures were time to onset of ESRD and renal function decline measured as the slope of the glomerular filtration Articles NATuRE MEDICINE rate (GFR). The latter assumed that long-term progressive renal decline is a constant linear loss of renal function 15 .
Results

Characteristics of discovery, validation and replication cohorts.
The study comprised two cohorts derived from the ongoing Joslin Kidney Study 12 : a discovery Joslin cohort of 219 subjects with T1D and a validation Joslin cohort of 144 subjects with T2D. Of the subjects, 96% of those with T1D and 82% of those with T2D were white. Study subjects had impaired kidney function (average estimated GFR (eGFR) of 45 ± 11 ml min -1 per 1.73 m 2 ) at baseline and were followed for a median of 8 years. A replication study was conducted in a cohort of 162 subjects with T2D who participated in the Pima Indian study 16 . These subjects were followed for a median of 11 years. In contrast to the Joslin cohorts, which had impaired renal function (late DKD) at baseline, the Pima cohort had normal renal function (average GFR = 155 ml min -1 ) (very early stage of DKD). Baseline and follow-up characteristics of the three cohorts are shown in Table 1 . The cohorts differed with regard to clinical characteristics, except for elevated albuminuria measured as the albumin:creatinine ratio (ACR) and rate of renal function loss over time estimated as GFR slopes, the latter two being similar among the cohorts. For the present study, in each cohort only cases of ESRD that developed during the first 10 years after study entry were considered. We found the following number of ESRD cases: 108 in discovery, 35 in validation and 38 in replication cohorts.
Search for kidney risk inflammatory signature associated with the development of ESRD. Baseline plasma specimens from the Joslin cohorts and baseline serum specimens from the Pima cohort were subjected to proteomics analysis using a customdesigned SOMAscan platform containing 194 inflammatory proteins. In the discovery Joslin cohort with T1D, baseline plasma concentrations of 35 proteins were significantly higher in subjects who developed ESRD than in those who did not (log 10 P > −3.6, nominal P value after Bonferroni's correction). The distribution of fold-changes according to the P values in this cohort is shown as a volcano plot in Fig. 1a . In the validation Joslin cohort with T2D, 17 of the 35 proteins had significantly higher concentrations in subjects who developed ESRD compared with those who did not (log 10 P > −2). These 17 proteins (indicated as red dots in Fig. 1a ) are considered in further analyses and are referred to as the kidney risk inflammatory signature (KRIS). Remarkably, in the replication Pima cohort with T2D, the baseline serum concentrations of 16 of the KRIS proteins were also significantly higher in subjects who developed ESRD compared with those who did not develop ESRD (P < 0.05).
The list of 17 KRIS proteins and fold-changes for each of them in the three cohorts are shown in Table 2 . The proteins were grouped to six TNF-receptor superfamily (TNF-RSF) members and eleven other proteins that included four receptors and seven secreted proteins. Despite different types of diabetes, different clinical characteristics and different ethnicity, the magnitude of fold-changes for these proteins was similar in the three study cohorts. It is interesting that the 17 KRIS proteins were significantly enriched in six (35%) TNF-RSF members. Among all 194 inflammatory proteins examined, these TNF-RSF members comprised only 12% (Fisher's exact P = 0.007). We saw no significant enrichment or depletion for other categories of inflammatory proteins (see Extended Data 1) . Results for the remaining 177 inflammatory proteins examined, which had no impact on the risk of ESRD or impact in one but not both Joslin cohorts, are presented in Supplementary Table 1 .
Effects of KRIS proteins on time of onset of ESRD.
As the Joslin cohorts had impaired renal function at baseline (advanced stage of DKD) and had almost identical fold-change values for each KRIS protein associated with the development of ESRD, the two cohorts were combined for further comparisons with subjects in the Pima cohort who had normal renal function at baseline. The effects of baseline concentrations of KRIS proteins on the time of onset of ESRD in the Joslin cohorts and the Pima cohort were examined using Cox's regression analysis. In the Joslin cohorts, all KRIS proteins were significantly associated with an increased risk of development of ESRD in univariable models, and in models adjusted for key potential confounders including age, HbA1c, eGFR and type of diabetes. The results of this multivariable model are shown in Fig. 1b . Among TNF-RSF members, the highest adjusted hazard ratios (HRs) for ESRD were seen for TNF-R1 (HR (95% CI) per one tertile change: 3.0 (2.2, 4.0); log 10 P = −13.0) and TNF-R2 (HR: 2.2 (1.7, 2.8); log 10 P = −9.4). Among the other KRIS proteins, the strongest association was detected for IL-15RA (HR: 2.4 (1.9, 3.0); log 10 P = −11.1). Strikingly, a similar pattern to that found in the Joslin cohorts was identified in the Pima cohort; baseline levels of 14 of the 17 KRIS proteins were significantly associated with the development of ESRD in the model adjusted for key confounders (age, GFR, HbA1c) (Fig. 1b) .
In models further adjusted for ACR, which we considered an intermediate phenotype, the HRs remained statistically significant for 15 of the 17 KRIS proteins in the Joslin cohorts, and 12 of the 17 proteins in the Pima cohort. Further adjustment by gender, systolic BP, BMI and diabetes duration did not substantially impact the effects of KRIS proteins in either the Joslin cohort or the Pima cohort (see Supplementary Table 2a,b) . BMI, body mass index; BP, blood pressure; CI, confidence interval. a In the Joslin cohorts, GFR was estimated using serum creatinine concentrations and was expressed as ml min -1 per 1.73 m 2 for baseline or ml min -1 per 1.73 m 2 per year for slope. In the Pima cohort, GFR was measured directly using urinary clearance of iothalamate and was expressed as ml min -1 for baseline or ml min -1 per year for slope. Incidence rate of ESRD is accompanied by the 95% CI. Mean and standard deviation or proportion measures are provided as applicable.
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KRIS proteins and long-term variation of renal function decline.
To examine whether KRIS proteins impacted the long-term disease process that leads to ESRD, we evaluated the relationship between concentrations of circulating KRIS proteins at study entry and longitudinal variations in renal function loss expressed as the GFR slope. In the Joslin Kidney Study, GFR slopes were estimated using serial measurements of serum creatinine, whereas, in the Pima Indian Study, slopes were estimated using serial measurements of GFR determined directly by iothalamate clearance. All KRIS proteins correlated strongly and inversely with the GFR slope in the Joslin cohorts. Correlations were somewhat weaker in the Pima Indians, but 14 of the KRIS proteins correlated significantly with the GFR slope and in a direction concordant with the Joslin cohorts (see Extended Data 2). These findings agree with the results of Cox's regression analysis with regard to the time to onset of ESRD shown in Fig. 1b .
Is the effect of KRIS proteins on renal function decline independent of albuminuria? In the present study, albuminuria is considered as an intermediate phenotype that is not a risk factor but a risk indicator of the disease process leading to onset of ESRD. To evaluate how much the effect of KRIS proteins on the rate of renal function decline was mediated through albuminuria, we conducted a mediation analysis. Figure 2a outlines the principles of the mediation analysis for TNF-R1 in the Joslin cohorts. This protein had significant albuminuria-independent (−9.3 ml min -1 per 1.73 m 2 per year per 1 log 10 of TNF-R1 increase) and albuminuria-mediated (−4.8 ml min -1 per 1.73 m 2 per year per 1 log 10 of TNF-R1 increase) effects. The total effect of 1 log 10 of increase in TNF-R1 on the eGFR slope was −14.1 ml min -1 per 1.73 m 2 per year. The proportion of the albuminuria-independent effect of TNF-R1 was 66%.
The detailed results of mediation analysis for all KRIS proteins are shown in Supplementary Table 3 . For most KRIS proteins, at least half of their effects on the GFR slope were through albuminuria-independent paths (range: 35-79% in Joslin and 55-72% in Pima cohorts, respectively). The total effect (albuminuria-independent and albuminuria-mediated) estimates were substantial. All KRIS proteins had significant effect on renal function decline in the Joslin cohorts except for CSF1, IL-1R1 and IL-18R1, whereas in the Pima cohort all had significant effect except for XEDAR, CCL15 and IL-18R1.
Correlations between the total effect estimates for all 17 KRIS proteins in the Joslin Kidney Study and the Pima Indian Study are shown in Fig. 2b . The strength of the correlations between the cohorts was remarkable (r = 0.73). The correlative pattern was preserved for all KRIS proteins. Overall, these results indicate a strong similarity in the disease process underlying the development of ESRD among the study groups.
Intercorrelation of KRIS proteins. For etiological considerations, correlated data may point to important underlying mechanisms. TNF-RSF1A  TNF-R1   TNF-RSF1B  TNF-R2   TNF-RSF21  D R6   TNF-RSF19  T ROY   TNF-RSF27  XEDAR   TNF-RSF19L RELT   Other proteins   IL-15RA  IL-15RA   IL-17F  IL-17F   CD55  DAF   CD300C  CLM6 TNF-SF15 TL1A and strengths of associations (P value on the y axis) with ESRD risk are presented in the discovery Joslin cohort with T1D. The fold-change is a ratio of the mean concentration of a protein in subjects who developed ESRD to mean concentration of the same protein in subjects who did not develop ESRD during follow-up. To test significance, a two-group comparison was used in the generalized linear model, with caseness as an independent variable and protein concentrations transformed to their base 10 logarithms as the respective dependent variable (two-sided P value). Thresholds for the significance used: in cohort with T1D: α = 0.00026 (Bonferroni's correction for 194 proteins measured); and in a validation Joslin cohort with T2D: α = 0.01. Seventeen significant proteins (KRIS), for which the associations were confirmed in the two Joslin cohorts, are marked with red dots; proteins that are significant in the Joslin cohort with T1D, but not confirmed in the Joslin cohort with T2D, are marked with dark-gray dots; non-significant proteins are marked with gray dots. Please see also Table 2 
TNF-RSF members
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We therefore examined, in the Joslin cohorts, intercorrelations among baseline concentrations of KRIS proteins using a hierarchical cluster analysis and a Spearman's rank correlation matrix (see Extended Data 3a-c). Both approaches demonstrated that most of the KRIS proteins are markedly correlated, suggesting mutual upstream mechanisms regulating the signature protein concentrations in circulation.
Is the kidney a source of circulating KRIS proteins? First, we determined whether the increased plasma concentrations of the KRIS proteins could be a consequence of dysfunctional kidney handling, resulting in retention of the KRIS proteins in the circulation. To answer this question we compared urine excretion of the 17 KRIS proteins in specimens obtained at baseline from subjects who had fast renal decline (cases) versus those who had no or slow renal decline (controls) during follow-up. From the T1D exploratory panel we selected 29 cases and 31 controls. Similarly, we selected 26 cases and 26 controls from the T2D validation panel. Clinical characteristics are shown in Supplementary Table 4. Baseline urine specimens were analyzed using the custom-designed SOMAscan platform. Fold-changes of baseline urinary excretion of KRIS proteins in cases over controls are shown in Extended Data 4. The results of this analysis are similar in T1D and T2D. Subjects at risk of ESRD had increased urinary excretion of KRIS proteins many years before the onset of ESRD. Three proteins topped the ranking: TNF-RSF21, CCL14 and IL-1R1. The excess urine excretion for the other proteins varied from moderate to minimal. None of the proteins showed lower urine excretion at baseline in subjects at risk of ESRD. These findings indicate systemic overproduction as a cause of elevated concentrations of circulating KRIS proteins, rather than impaired renal handling.
Second, we examined whether the increase in circulating KRIS proteins might be a consequence of overexpression in kidney genes encoding for KRIS proteins [17] [18] [19] . For this analysis we examined the correlation between levels of circulating KRIS proteins and their corresponding gene expression in kidney biopsies obtained from 56 Pima Indians within ± 6 months of the SOMAscan determinations 17, 18 . We found no correlation between circulating levels of KRIS proteins and tubular expression of their corresponding genes. There was only moderate correlation between circulating levels of TNF-R1 and TNF-R2 and glomerular expressions of these genes: TNF-R1, r = 0.34; TNF-R2, r = 0.27, respectively. Concentration of the other KRIS proteins did not show any correlation with glomerular expression of the genes encoding for these proteins (see Extended Data 5) .
Third, we examined the expression of the mRNA of genes encoding for the KRIS proteins in kidney specimens from the 1,000 Kidney Genomes Project (1KGP) (see Supplementary Table 5) 19 , selecting subjects with similar phenotypic characteristics to our Joslin cohort with T2D. Glomerular and tubulointerstitial mRNA expression data were available for 12 KRIS protein-coding genes. In the glomeruli, mRNA levels of CD55 and IL-1R1 were positively and strongly correlated with histopathological indices of DKD, such as glomerular TAJ (TROY), toxicity and JNK inducer; XEDAR, X-linked ectodermal dysplasia receptor; RELT, receptor expressed in lymphoid tissues; DAF, decay accelerating factor for complement; CLM6, CMRF35-like molecule 6; HCC1, hemofiltrate CC chemokine 1; MIP5, macrophage inflammatory protein 5; M-CSF, macrophage-colony-stimulating factor; TIMD3, T cell immunoglobulin and mucin domain-containing protein 3. Fold-change is a ratio of the mean concentration of a protein in subjects who developed ESRD to the mean concentration of the same protein in subjects who did not develop ESRD during follow-up. Significance was tested in the generalized linear model (two-sided P value). ¶ Thresholds for the significance for the Joslin cohorts have been described in the Fig. 1 legend. In the replication Pima cohort with T2D, 16 proteins were replicated at P < 0.05 (equivalent to log 10 P < -1.3).
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KRIS proteins and proliferative diabetic retinopathy.
To determine whether KRIS is specific to DKD or also plays a role in other diabetic complications, we examined the relationships between circulating KRIS proteins and the prevalence of proliferative diabetic retinopathy (PDR) in a sample of subjects with T1D from the Joslin Kidney Study for whom eye and SOMAscan data were available (n = 180; see Supplementary Table 6 ). In the logistic regression analysis adjusted for HbA1c, eGFR and ACR, none of the KRIS proteins was associated with prevalent PDR (see Extended Data 7). The odds ratios (OR) of PDR per one tertile change of TNF-R1 was OR (95%CI): 0.82 (0.42, 1.61); P = 0.564.
Ligand binding to TNF-RSF members and development of ESRD.
As the KRIS was enriched in members of TNF-RSF, we next examined proteins of the entire TNF-RSF and their corresponding ligands. The TNF-RSF consists of 30 members, 23 of which were included in our array. We constructed a network of the TNF-RSF together with the corresponding TNF ligand superfamily (TNF-SF) ( Fig. 3 ). Binding patterns between ligands and receptors were curated based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway maps, with support from reports that focused on studying ligand-receptor binding of this particular family [20] [21] [22] . Although TNF-R1 and TNF-R2 were the most robust predictors of ESRD risk, their corresponding major ligand (TNF) was not associated with ESRD risk. This was also true for other significant TNF-RSF members and their corresponding ligands. Some additional TNF-RSF and TNF superfamily (TNF-SF) members did not fulfill the criteria of significance in the initial screening (fold-change analysis), but were still highly significant in Cox's regression analysis (for example, TNF-RSF4 (OX30), TNF-RSF9 (4-1BB), TNF-SF7 (CD70) and TNF-SF12 (TWEAK), log 10 P < −10 for either).
Treatment of DKD and changes in circulating KRIS protein levels.
To examine the effect of renin-angiotensin-system inhibitor (RASi) treatment on circulating KRIS levels, we examined levels in 137 of the Pima Indians who were participating in a randomized clinical trial of losartan at the time of the SOMAscan measurement 23 ; 68 patients were in the placebo arm and 62 in the losartan arm. They received the study drug for at least 6 months before the KRIS protein measurements. This treatment did not have any effect on KRIS protein profiles (Fig. 4a) .
To examine the effect of the JAK1/2 inhibitor, baricitinib, on circulating KRIS protein levels, we acquired plasma specimens from a subset of participants with advanced DKD from a phase 2 clinical trial 24 (see also Supplementary Information). KRIS protein levels were measured at baseline and 24 weeks after initiation of treatment with baricitinib 4 mg daily or placebo. Ten KRIS proteins were measured on the Olink platform (see Supplementary Information). Baricitinib treatment resulted in significantly decreased concentrations of plasma TNF-R2, CD300C, HAVCR2 and IL-1R1 (repeated measure estimate for a difference in change over time in plasma TNF-R2 in the 17 subjects treated with baricitinib group versus the 25 treated with placebo was estimated as β ± standard error: 1.13 ± 1.06, P = 0.045). The tendency to decrease plasma protein levels was also observed in the 4 mg dose group versus the placebo group for all but two of the remaining proteins. Importantly, there were no significant changes in the protein levels in the placebo group over time (Fig. 4b) .
Other therapies currently being tried for other indications (see Supplementary Table 7 ) may also be effective in slowing renal For example, an increase in one log 10 unit of TNF-R1 is associated with a rapid eGFR loss of 14 ml min -1 per 1.73 m 2 per year, meaning that a typical Joslin cohort study subject with T1D who had proteinuria and chronic kidney disease (CKD3) would develop ESRD in 3 years. Mediation models are described in the text. b, Correlation plot of the total effects of KRIS proteins between the Joslin cohorts and the Pima cohort. The total effects represent β estimates of eGFR loss in ml min -1 per 1.73 m 2 per year (Joslin cohorts, n = 363) and of GFR loss in ml min -1 per year (Pima cohort, n = 162) for an increase of one unit of a KRIS protein transformed to its base 10 logarithm. The model is adjusted for age, HbA1c, baseline eGFR (Joslin study) or GFR (Pima study), whereas ACR is evaluated as a mediator of the effect (two-sided P values). The total effect estimates for TNF-RSF members are marked with red dots and for other KRIS proteins with black dots. Spearman's rank coefficient and corresponding P value (upper right-hand side) represent correlations between the total effect estimates of the cohorts. All P values are two sided. Please see the corresponding Supplementary  Table 3 for details on effect decompositions.
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KRIS proteins as predictors of time of onset of ESRD.
Although our main goal was to develop an etiological model of DKD, we also evaluated the predictive value of the KRIS proteins for 10-year ESRD risk in the combined cohorts (Joslin with T1D, Joslin with T2D and Pima Indian studies, respectively). Five KRIS proteins (TNF-R1, XEDAR, IL-17F, TNF-SF15 and CCL15) predicted ESRD (see Supplementary Table 8 ). The addition of TNF-R1 to the clinical model increased the concordance statistic (C-statistic) from 0.81 to 0.84 (P = 0.001). Adding the other four KRIS proteins further improved discrimination (C-statistic: 0.86, P = 0.007). The model fit was also improved with TNF-R1 (P < 10
) and the other KRIS proteins (P < 10
−6
).
Discussion
We identified a KRIS comprising 17 circulating inflammatory proteins, which were strongly associated with the development of ESRD but not with proliferative diabetic retinopathy. These findings apply to subjects with T1D and T2D, white individuals and Pima Indians, and to those with early and advanced stages of DKD. These findings add 15 new proteins to our previous discovery that circulating levels of TNF-R1 or TNF-R2 were robust predictors of early and late renal function decline, leading to ESRD in T1D and T2D 4, 5, 7 . The present study did not confirm previous reports that implicated various circulating inflammatory proteins, including TNF-α, interleukin 6 (IL-6) and monocyte chemoattractant protein 1 (MCP1)/CCL2, in the development of DKD.
The signature comprising KRIS proteins was enriched in members of the TNF-RSF. Six TNF-RSF members were robustly associated with renal outcomes: TNF-R1, TNF-R2, TNF-RSF19 (TROY), TNF-RSF27 (XEDAR) and TNF-RSF19L (RELT). TNF-R1 and TNF-R2 have been studied previously as predictors of progressive renal decline that leads to ESRD [4] [5] [6] [7] [8] [9] [10] [11] 25 . They mediate a broad range of biological activities, including cell survival, proliferation and death, together with a variety of inflammatory and immunomodulatory responses linked to kidney diseases 26 . By contrast, the remaining TNF-RSF members were not implicated in the development of DKD and their biology is less well known. They were investigated previously in the context of neurologic (TNF-RSF21 (DR6), TNR-SF19 (TROY)), skin (TNF-RSF19; TNF-RSF27 (XEDAR)) and hematologic disorders (TNF-RSF19L (RELT)) [27] [28] [29] . IL-15RA was the top non-TNF-RSF protein included in the KRIS proteins. IL-15RA mediates pleiotropic proinflammatory signals involved in several inflammatory disorders. However, neither IL-15RA nor its ligand has ever been studied in the context of DKD 30 . Of the other KRIS proteins, IL-17F, CD55 (DAF), CSF1 (M-CSF), and receptors 1 for interleukins 1 and 18 (IL-1R1, IL-18R1) were previously reported in the context of DKD, although mainly in functional or cross-sectional studies 2, 3, [31] [32] [33] . CC chemokines, mainly CCL2 (MCP1) and CCL5 (RANTES), are postulated to be involved in DKD 2, 34 . Surprisingly, in the present study these two were not associated with ESRD. By contrast, CCL14 (HCC1) and CCL15 (MIP5) were part of the KRIS. The latter two chemokines are involved in the immune responses via mediation of monocyte activation 3, 35, 36 . In general, TNF-RSF members correlated strongly among each other as well as with other selected KRIS proteins: IL-15RA, CD55 and HAVCR2. The biological meaning of this clustering pattern needs to be determined.
The source and determinants of KRIS proteins that appear many years before the onset of ESRD are not clear. Urinary proteomic data 
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NATuRE MEDICINE from the Joslin cohorts provide compelling evidence that overproduction rather than dysfunctional renal handling is responsible for the increased concentrations of the KRIS proteins in the circulation. However, data from the Pima Indians suggest that overproduction of the KRIS proteins takes place outside the kidneys. Similarly, there were inconsistent relationships between genes expressing KRIS proteins and histopathological indices of DKD in kidney biopsies obtained in the 1KGP. It is interesting that the vast majority of current research utilizing high-throughput technologies concentrates on the kidney as the primary driver of the disease 37 ; by contrast, our findings highlight the importance of non-kidney factors as important etiological drivers of DKD.
Leukocytes are one plausible non-kidney source of the KRIS proteins. Indeed, previous evidence suggests the involvement of both innate and adaptive immune responses in the development of DKD. Macrophages are the most prevalent infiltrating leukocytes found in diabetic kidneys and are associated with declining renal function. In addition, white blood cells and their fractions correlate with the structural lesions of DKD in Pima Indians and predict renal function loss in white individuals with T2D. The KRIS proteins comprised molecules mainly involved in innate immune responses, many of which are expressed by monocytes. However, IL-17F is an interleukin involved in adaptive responses mediated by a subset of T cells (Th17) 2, 3, 32, 33, [38] [39] [40] [41] . The traditional paradigm presumes that TNF-RSF members transduce their intracellular signals induced by upstream binding of their cognate ligands, although limited evidence also suggests that TNF-RSF proteins may act via ligand-independent mechanisms 22 .
In the present study, associations of the TNF-SF with renal outcome were negligible. Notably, TNF-α was among these unimportant ligands. This is in contrast to previous studies in other populations reporting TNF-α involvement in DKD. Those studies, however, focused on associations with albuminuria, and studied subjects with established disease rather than those at risk 2, 3 . If the KRIS proteins are involved in the etiology of renal function loss, targeting these molecules and the involved inflammatory pathways may help identify new drugs to prevent ESRD. So far only a few interventions targeting KRIS protein-involved pathways have been conducted in DKD. Furthermore, as all KRIS proteins are strongly associated with the risk of ESRD, effective therapies that impact the disease process flagged by these proteins should reduce the levels of some or all of the KRIS proteins during intervention.
A phase 2 randomized clinical trial of baricitinib, a JAK1/2 inhibitor, decreased albuminuria (primary outcome) after 24 weeks of treatment in participants with a comparable baseline renal phenotype to our Joslin study cohort with T2D 24 . This cohort was used to further evaluate changes in circulating KRIS protein levels due to JAK1/2 inhibition. Baricitinib significantly decreased levels of a number of KRIS proteins (including TNF-R2) at week 24 with administration of 4 mg baricitinib relative to placebo. Our results confirm and expand already published findings that demonstrated a reduction in plasma TNF-R2 after baricitinib treatment 24 . This interventional study had a relatively small sample size and a short follow-up. It is possible that longer exposure to JAK1/2 inhibitory treatment may result in more pronounced changes in KRIS proteins.
We found no evidence that losartan reduced the levels of KRIS proteins in the Pima Indians. The effect of sodium-glucose transport protein 2 inhibitors or glucagon-like peptide 1 agonists on the levels of these proteins has not been assessed, but small studies of CCL2 inhibitors, pentoxifylline and anti-TNF agents found reduced levels of selected KRIS proteins in DKD after treatment 2, [42] [43] [44] [45] [46] . It is interesting that many other biological inhibitors targeting KRIS protein-involved pathways are currently being tested in clinical trials for other chronic inflammatory disorders, including rheumatoid diseases, inflammatory bowel disease, asthma and others [47] [48] [49] [50] [51] . Some of these compounds were also examined in functional studies of kidney injury. Infliximab (anti-TNF monoclonal antibody) and etanercept (TNF-R2-Fc), for example, decreased albuminuria in animal models of diabetes 42, 46 . Blockade of IL-17 decreased renal fibrosis in uninephrectomized rats undergoing ischemia-reperfusion insult 51 . Treatment with CCR1 antagonists (CCR1 is a receptor for CCL14, CCL15) decreased kidney fibrosis and interstitial inflammation in animal models of DKD and glomerulonephritis 52, 53 . Further testing of these compounds in DKD may be warranted.
Independent of the role of the KRIS proteins in the etiology of DKD, these proteins may be used for two other purposes: (1) to develop a prognostic test to identify individuals at higher risk of progression to ESRD and (2) as a surrogate outcome measure where changes in KRIS protein levels during intervention may reflect the effectiveness of the tested therapy. Whereas the main aim of our etiological study was to identify inflammatory proteins involved in the disease process leading to ESRD, the goal of a prediction study The effect estimate on the y axis is based on the longitudinal analysis of response profiles per unit of a protein change transformed to its base 10 logarithm. Red bars denote proteins for which differences in KRIS protein levels were significantly different over time (P < 0.05) in the treated group compared with placebo. Gray bars denote unsubstantial changes. Protein measurements were performed using Olink Inc. technology.
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is to measure the probability of the development of ESRD during follow-up, using a combination of the smallest number of biomarkers/clinical characteristics. The biostatistical approaches used to address these two goals are distinct. Etiological studies are inclusive and welcome correlated features, whereas predictive studies favor selection of uncorrelated factors and focus on discriminatory metrics. Our etiological modeling led to identification of 17 relevant KRIS proteins, whereas predictive modeling reduced the selection to just 5. The prognostic performance of circulating levels of TNF-R1 has been evaluated by us previously 12 .
In this report we found four additional proteins that, when measured together with TNF-R1, increased the model's ability to predict ESRD risk.
The strengths of the present study include long-term follow-up observations of multiple cohorts, the use of reliable outcome measures and use of the SOMAscan platform to measure the concentration of proteins in each cohort. As the study was conducted exclusively in subjects with diabetes, we have no data to evaluate the generalizability of these findings to individuals with other kidney diseases.
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Methods
Overall study design. To test the hypothesis that a common inflammatory process contributes to the development of ESRD in both types of diabetes, we used followup studies of three independent cohorts: discovery (Joslin cohort with T1D), validation (Joslin cohort with T2D) and replication (Pima cohort). The Joslin Kidney Study subjects with T1D were chosen as the discovery cohort to identify a signature of circulating inflammatory proteins associated with the development of ESRD, because the natural history of DKD in T1D is more homogeneous. As subjects with T2D have DKD that is often confounded by comorbidities, the Joslin cohort with T2D was used to validate findings obtained in T1D. The replication cohort of Pima Indians with T2D was used to examine the importance of candidate inflammatory proteins found in late DKD in subjects with an early stage of DKD and also those of different ethnicity. The latter population has a high risk of developing ESRD.
Joslin Kidney Study: selection of discovery and validation cohorts. The Joslin Diabetes Center Committee on Human Studies approved the informed consent, recruitment and examination procedures for the Joslin Kidney Studies, as well as for the current research. The Joslin Clinic is a large clinic within the Joslin Diabetes Center that provides health care for about 20,000 subjects (85% of them white) of all ages and with both types of diabetes, who reside mainly in the eastern part of Massachusetts. Most patients are referred to the clinic within the first 5 years of a diagnosis of diabetes and a large proportion remains under the care of the clinic for a long time, frequently for life. Over the last 25 years about 3,500 subjects attending the Joslin Clinic were enrolled into a longitudinal study referred to as the Joslin Kidney Study, which aims to identify determinants of the onset and progression of DKD 15, [54] [55] [56] . All enrolled subjects had baseline and follow-up examinations performed with blood and urine specimens collected and stored at -85 °C for future examinations. Those who had stopped coming to the clinic were examined at their homes. All subjects included in the Joslin Kidney Study are being queried every 2 years against rosters of the United States Renal Data System (USRDS) and the National Death Index (NDI) to ascertain who developed ESRD or died. The last inquiry was conducted in 2015. The USRDS maintains a roster of US patients receiving renal replacement therapy, which includes dates of dialysis and transplantation. The NDI is a comprehensive roster of deaths in the US that includes date and cause of death. Participants were classified to either T1D or T2D according to standard clinical criteria, among which treatment with insulin from the onset of diabetes was required to diagnose the former and treatment with diet or oral agents to diagnose the latter.
The present study includes a subset of subjects enrolled into the Joslin Kidney Study who participated in our previous study to determine a threshold value of plasma TNF-R1, for the prediction of progression to ESRD 12 . In contrast to the previous study, which included individuals with CKD stages 3 and 4, the present study includes individuals with CKD3 for whom baseline samples were available for the proteomics analysis. In total, the study comprised 219 subjects with T1D (exploratory cohort) and 144 with T2D (validation cohort), who were enrolled into the Joslin Kidney Studies between 1991 and 2006; they were followed to ascertain renal function changes by estimating eGFR slopes and dates of onset of ESRD and deaths. As of 2015 the duration of follow-up was 8 years (median) and 6 and 11 years (25th and 75th percentiles) among subjects who did not develop ESRD. Among those who developed ESRD, the duration of follow-up was 4 years (median) and 2 and 6 years (25th and 75th percentiles). A description of the cohorts, measurements of clinical characteristics, determinations of eGFR slopes, and ascertainment of ESRD and deaths were included in the previous publication 12 (see also Supplementary Information). Plasma and urine specimens obtained from subjects included in the present study were obtained at enrollment and were stored at -85 °C until assay on the SOMAscan proteomics platform in 2016.
Pima Indian Study: selection of the replication cohort. The study was approved by the Institutional Review Board of the National Institute of Diabetes and Digestive and Kidney Diseases. Each subject gave informed consent at each renal clearance study.
Pima Indians from the Gila River Indian Community in Arizona have both a very high prevalence of T2D and a high incidence of ESRD due to diabetes 57 . This population participated in a longitudinal study of the natural history of diabetes and its complications between 1965 and 2007. Informative subsets of individuals from this population were selected, beginning in the late 1980s, to undergo more detailed longitudinal studies of DKD, and follow-up of many of these individuals still continues 16, 57 . For our research we used a cohort of 310 adults enrolled in these Pima Indian kidney studies who had renal function measured longitudinally using urinary clearance of iothalamate; GFR was expressed as ml min -1 . In contrast, in the Joslin Kidney Study GFR was estimated using serum creatinine concentrations and expressed as ml min -1 per 1.73 m 2
. More information about measurements of clinical characteristics, including iothalamate GFR, obtaining specimens at baseline and outcome ascertainment, is described in a previous publication 16 . For the Pima replication cohort we selected 162 subjects who had normal renal function at the start of the study (between 1994 and 2007), had a sufficient amount of serum for SOMAscan analysis and did not develop ESRD during a follow-up of at least 4 years (three or more GFR measurements), so GFR slopes could be determined. As of 2017, the duration of follow-up was 11 years (median) and 10 and 13 years (25th and 75th percentiles) among subjects who did not develop ESRD. Among those who developed ESRD, the duration of follow-up was 7 years (median) and 4 and 10 years (25th and 75th percentiles). For the present study we right-censored the length of the follow-up at 10 years. Within this timeframe, 38 study subjects developed ESRD and 124 remained ESRD free.
Of the 162 subjects included in the replication cohort, 137 also participated in a randomized clinical trial of losartan. From those 137 participants, 68 were in the placebo arm and 62 in the losartan arm, and received the study drug for at least 6 months before the KRIS protein measurements 23 . Serum samples obtained from the 162 Pima Indians, at initiation (between 1994 and 2008) of follow-up, underwent proteomic profiling with the same aptamer-based technology on the SOMAscan platform as plasma samples obtained from the Joslin Kidney Study. Measurements in the Pima Indians were performed in 2017. Baseline serum samples were stored at -80 °C before assay.
SOMAscan: aptamer-based proteomic profiling. Unique single-stranded sequences of DNA or RNA, referred to as aptamers, were demonstrated to recognize folded protein epitopes with high affinity and specificity. This property was further advanced by the Slow Off-rate Modified Aptamer (SOMAmer) utilized on the SOMAscan platform to assay concentrations of proteins in the present study. This proteomic platform features high-throughput capabilities (over 1,000 proteins in one sample), together with excellent reproducibility and sensitivity 13, 14 . Applications of this aptamer-based technology in large epidemiological studies have been used in other disease settings [58] [59] [60] . The present study evaluated assay results for 194 inflammatory proteins present on a SOMAscan array. The protein selection algorithm implemented for the SOMAscan platform incorporated a strong preference toward proteins known to be present in circulating matrices such as plasma or serum. The selection included representatives of major inflammatory classes: interleukins, chemokines, TNF-SF, and the corresponding receptors of the three groups, interferons, complement system members and co-stimulatory molecules. Intracellular mediators of inflammation were not considered in our array because they were unlikely to be detected in circulating matrix.
Plasma (from the Joslin cohorts) and serum (from the Pima cohort) samples were run in batches of 78 samples, balanced by prospective case status and masked to the laboratory operators and data-processing scientists. Twelve replicate samples were applied across the batches to allow for universal calibration, based on intercept and β estimates from the linear regression model drawn from PROC GLM in SAS. Replicate samples were used to generate coefficients of variation (CVs). Overall, the assay precision was very good. The median interassay CV for all 194 proteins was: 4.3% (25th, 75th percentile: 3.0%, 6.4%, respectively); 174 proteins (90%) had CVs below 10% and only 3 proteins were characterized by marked variation (CVs > 20%). The CVs are listed in Supplementary Table 1 .
Plasma samples from the 219 Joslin Kidney Study participants with T1D had TNF-R1 and TNF-R2 measurements performed using Quantikine ELISA assays (catalog numbers: DRT100, DRT200, RnD Systems) 12 . Spearman's rank correlation coefficient between antibody-based measurements and aptamer-based measurements was r = 0.98 for TNF-R1 and r = 0.95 for TNF-R2.
Urine profiles of the KRIS proteins and progression to ESRD. Urine samples from a nested case-control study of subjects from the Joslin cohorts with T1D and T2D underwent profiling of the proteins of interest using the same aptamer-based SOMAscan technology. The array readout contained the same set of 194 proteins described above, but only the 17 proteins of interest identified in the plasma samples were analyzed.
T1D cases (n = 29) were identified from among subjects with T1D of the discovery panel who experienced fast progressive renal decline (eGFR loss > 8 ml min -1 per year). Most of the cases developed ESRD within 10 years of observation. Controls with T1D (n = 31) were selected from among those with T1D who had no or minimal renal decline (eGFR loss < 3.5 ml min -1 per year) within the follow-up period. Cases with T2D (n = 26) and controls (n = 26) were drawn from among the subjects with T2D of the validation panel, following the same eligibility criteria as those with T1D. Comparisons of characteristics of the study groups are shown in Supplementary Table 3 . Urine samples were also measured using the aptamer-based technology described above. Obtained concentrations were normalized to the urine creatinine concentration. The distributions of urine proteins featured departures from normality, so the effect sizes were reported as fold-changes of median values per group, compared with serum/plasma proteins for which the effect size was based on fold-changes of mean values per group.
Kidney tissue mRNA expression data of KRIS proteins: Pima Indian Study.
The relationships between transcriptional regulation and quantitative structural damage in early DKD were examined in a subset of the Pima cohort. From the cohort of 162 Pima Indians, 49 underwent protocol kidney biopsies and had sufficient tissue for evaluation of the tissue gene expression within 1-2 years of the serum SOMAscan measurements. Kidney tissue was subjected to compartment-
Articles
were similar to the characteristics of the entire cohort from which it was drawn, as described earlier 10 . Profiling of gene expression was performed using a GeneChip Human Genome series U133A and Plus 2.0 Array (Affymetrix). Image files (Affymetrix) were processed as described previously 17, 18 . Kidney tissue mRNA expression data of KRIS proteins: 1KGP. Tissue expression of mRNA-encoding proteins of interest in the present study was derived from the 1KGP collection 19 . Tubular (n = 37) and glomerular (n = 23) mRNA expression was derived from subjects with T2D, various ethnic ancestries and overt DKD (for clinical characteristics and histology indices, please refer to Supplementary Table 5 ). Kidney samples were obtained from routine surgical nephrectomies, stored in RNAlater (Ambion), and manually microdissected under a microscope to separate the glomerular and tubular compartments. RNA quality and quantity were determined using the Laboratory-on-Chip Total RNA PicoKit Agilent BioAnalyzer, and only samples without evidence of degradation were used (RNA integrity number > 6). Purified total RNAs were amplified using the Ovation Pico WTA System V2 (NuGEN) and labeled with the Encore Biotin Module (NuGEN), according to the manufacturer's protocol. Transcript levels were analyzed using Affymetrix U133A arrays, and raw expression levels were summarized using the RMA16 algorithm by the justRMA function of the Affymetrix package. Details on clinical characteristics and histology indices are provided in Supplementary Table  5 . Proteinuria was determined with a dipstick score of 0-5.
An interventional study of baricitinib in DKD. This study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization, and local laws and regulations. The study protocol and informed consent forms were approved by institutional review boards or ethics review boards for each study site.
This was a phase 2 trial that was randomized, placebo controlled, double blind, parallel group and dose ranging (ClinicalTrials.gov identifier NCT01683409). The study design included a 24-week treatment with baricitinib, accompanied by the respective screening and washout periods. Baricitinib is a selective inhibitor of JAK1/2. Eligibility criteria allowed for recruitment of patients with comparable renal phenotypes to the Joslin cohort with T2D (T2D, 25 ≤ eGFR ≤ 70 ml min ). The study met its primary endpoint with evidence of significant reduction of albuminuria after the baricitinib treatment. Details of the study design, clinical characteristics of the participants and the main results were published elsewhere 24 . From among the 129 study participants, 25 were in the placebo group and 17 were in the highest baricitinib dose (4 mg) group. Those who completed treatment, and for whom plasma samples at baseline and 24 weeks of treatment were available, were subjected to the targeted proteomic measurements.
Of the 17 KRIS proteins 10 were measured with the proximity extension assay using the Olink Inc. panels ). All paired samples were run within a respective single plate. All data-points were within the detection limits. The intraassay CV was below 10% for all the proteins except for TNF-RSF19L, for which the CV was 11.5%.
Protein nomenclature. The HGNC is the worldwide authority that assigns standardized nomenclature to human genes. HGNC symbols were used to describe protein symbols throughout the manuscript, although TNF-R1 and TNF-R2 were also used to describe TNF-RSF1A and TNF-RSF1B, because these names are familiar to most readers 62 .
Statistical analysis. The descriptive characteristics were provided as mean and standard deviations, median (25th and 75th percentile) or proportions, as applicable. Multivariate generalized linear modeling of the global proteomic profiling data was performed to generate effect sizes as fold-changes of means in two groups (ESRD progressors versus non-progressors), together with significance adjusted for multiple testing using Bonferroni's correction. Enrichment in TNF-RSF members was conducted using two-sided Fisher's exact tests over a background of 194 inflammatory proteins. The overrepresentations of certain protein classes among the significant proteins were compared with all protein members of the respective class, and referenced against proportions of the remaining significant and non-significant proteins measured within the array as described previously 63 . Please note that our customized array constitutes a background already 'enriched in the inflammatory molecules' , which may unfairly lower the robustness of the analysis. Significant enrichments in the context of this unfavorable background imply that these enrichments must be particularly strong. Multivariable Cox's proportional hazards models tested associations of relevant proteins with the primary outcome (time to ESRD censored at 10 years), expressed as HRs per one tertile change of the percent rank marker distribution, with corresponding 95% CIs (one degree of freedom). Ties in the failure time were handled with exact conditional probabilities. We examined potential confounding by inspection of β estimates, and change in β of 20% or higher was considered non-negligible. Martingale's residual plots were examined to test the proportional hazards assumption. Plots showing that the observed curves for a variable were within the distribution of the simulated, cumulative, Martingale's residual curves were indicative of an acceptable fit. In parallel, a significant P value at the level 0.05 was considered a poor fit. Proportionality assumption was tested for final univariable and adjusted models.
Longitudinal trajectories of GFR measurements over time were constructed using linear regression models. Associations of KRIS proteins with GFR slopes were evaluated based on Spearman's rank correlation coefficients. Correlation coefficients and nominal P values are provided.
Mediation analysis advances our knowledge about the mechanisms by which an exposure affects an outcome, and assists in evaluating whether the intervention on the mediator could possibly reduce the effect of exposure. We built our etiological model with renal function decline, expressed as GFR slope, as our dependent variable. Albuminuria was included as a mediator (M) of KRIS protein effects. In principle, the mediation analysis that assumes no interaction relies on the two regression models: E(M|A = a,C = c) = β 0 + β 1 a + βʹ 2 c and E(Y|A = a,M = m,C = c) = θ 0 + θ 1 a + θ 2 m + θʹ 4 c, where M is the mediator, A the exposure, C the confounding variables, and Y the outcome, and the vertical bar denotes the model conditional upon the following variable. The natural direct effect (NDE) can be expressed as NDE = θ 1 (a -a * ) and natural indirect effect (NIE) as NIE = θ 2 β 1 (a -a * ). NDE quantifies the impact of the exposure on the outcome if the path between the exposure and the mediator was disabled. NIE determines the effect of exposure on the outcome operated by modulating the mediator levels. For causal interpretations, one must assume that the model was correctly specified and controlled for exposure-mediator, mediator-outcome and exposure-outcome confounding, that none of the mediator-outcome confounders were themselves affected by the exposure and that the temporal relationships were preserved. We did not have sufficient power to perform mediation analysis using time to ESRD as our outcome. PROC CAUSALMED in SAS software was used 64 .
Orthogonal relationships among proteins of interest were evaluated with the tools of hierarchical cluster analysis (Ward's method) and matrices of Spearman's rank correlation coefficients. Spearman's rank correlation coefficients were calculated to examine the correlation between gene expression and CKD traits (glomerular sclerosis, tubulointerstitial fibrosis and interstitial lymphocytic infiltrate) in the 1KGP study, and between gene expressions and corresponding circulating protein levels (in the Pima Indian Study). Cross-sectional associations between plasma KRIS proteins and retinopathy were evaluated using a logistic regression analysis per one tertile change of the percent rank marker distribution with corresponding 95% CIs (one degree of freedom).
We evaluated prediction performance in Cox's proportional hazards model, applying forward variable selection (entry criterion, P = 0.1) to the dataset comprising the three cohorts. Considerations were inclusive for all potentially relevant clinical variables (age, gender, diabetes duration, HbA1c, GFR or eGFR, ACR (transformed to its base 10 logarithm), systolic BP, BMI, cohort indicator) and for all 17 KRIS proteins. The model resulted in the selection of five KRIS proteins including TNF-R1 and selected clinical covariates (model no. 3). We compared model no. 3 with the model containing the same clinical covariates and TNF-R1 (model no. 2). The simplest model (no. 1) contained clinical covariates only. Prediction discrimination was measured with metrics suitable for rightcensored data. Harrell's C-statistic was calculated as proportions of pairs for subjects whose observed and predicted outcomes were concordant, where pairs incomparable due to censoring were discarded. Uno's method yielded similar values of the C-statistic. The fit of the consecutive nested models was tested using likelihood ratio tests with the appropriate degrees of freedom and an assumption of Χ 2 distribution, and by changes in the Akaike information criterion values.
Longitudinal changes of KRIS proteins as a result of the interventional studies were evaluated with the analyses of response profiles (PROC MIXED with REPEATED statement) that account for within-individual variation. Models evaluated changes in proteins transformed to their base 10 logarithms and included treatment arm, visit and treatment arm × visit interaction, with the restricted maximum likelihood as the estimation method. An unstructured covariance structure was used.
We evaluated our models in the testing framework of a two-sided α error = 0.05 unless otherwise noted. Analyses were performed in SAS v.9.4.
Pathway analysis. The binding patterns between the TNF-SF ligands and receptors were curated based on the KEGG pathway maps and additional reports focusing on the study of ligand-receptor bindings of this family 20, 21 .
Literature search on therapeutic targets. A non-systematic literature search on the utility of the potential therapeutic targets relied on a number of resources: (1 T N F -R S F 2 7
Extended Data Fig. 4 | KRIS proteins in the urine and development of ESRD. Aptamer-based, urinary creatinine-adjusted KRIS protein profiles and development of ESRD in nested case-control studies selected from a, Joslin cohort with T1D (n = 60) and b, Joslin cohort with T2D (n = 52). Effect size (fold-change) is presented. Urinary proteins significant for corresponding thresholds used in multivariate screening for plasma proteomics study (twosided) are marked with dark red bars. r
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All global proteomic profiling data coming from the prospective study of 3 cohorts followed for ESRD risk supporting our findings are provided in the Supplementary
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information of this article. Raw datasets may be available to investigators upon reasonable requests. A web-based database of all the proteomic and metabolomic profiling data of the Joslin Kidney Study will be launched soon to allow single query-based searches of the compounds and their associations with renal outcomes.
Field-specific reporting All studies must disclose on these points even when the disclosure is negative.
Sample size
There are no prior studies using this untargeted proteomic technology to study determinants of diabetic kidney disease, so we had no prior knowledge regarding the potential effect size. Nevertheless, our previously published targeted study of a population comparable in size revealed the association between the biomarker and progression to ESRD in the strength of a p value: p<10-12 (PMID: 22266663). Our untargeted proteomic study imposes a Bonferroni correction for a number of biomarkers measured (n=194) and that results in alpha: α = 2.5 x 10-4. Our current study is sufficiently powered to detect associations of the biomarker with the renal outcome of comparable strength to the previously reported and even those biomarkers with smaller strength of associations. Please note that our study population comprises 3 independent prospective cohorts.
Data exclusions There were no data exclusions.
Replication
Our prospective study design comprised 3 independent cohort studies of subjects with both diabetes types and varying ethnic ancestries. We rigorously adjusted our results for multiple testing: Bonferroni correction in the discovery panel, nominal alpha = 0.01 in the validation panel and nominal alpha = 0.05 in the confirmation panel. Our signature comprising 17 proteins was significantly robust in the discovery and validation panel (by design) and 15 out of 17 proteins were confirmed further in the confirmation panel.
Randomization Randomization was not applicable to our study design. Confounding was controlled in the study design phase (restriction to certain stages of chronic kidney disease or albuminuria) together with evaluation of potential confounders or mediators in the multivariable models.
Blinding
The Somalogic research team performing outsourced proteomic measurements were blinded to the caseness status of the samples. Samples were balanced by caseness in-house prior to sending the specimens. Otherwise blinding was not applicable.
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